Navigation Links
WallSt.net Announces Upcoming Interview with CEO of BioSante Pharmaceuticals
Date:9/24/2007

NEW YORK, Sept. 24 /PRNewswire/ -- Stephen Simes, chief executive officer of BioSante Pharmaceuticals, Inc. (Amex: BPA) (http://www.biosantepharma.com) will be featured in an exclusive interview with http://www.wallst.net scheduled for September 26 at 10:30 a.m. EDT. The interview will be posted on http://www.wallst.net by 8 p.m. EDT on September 26.

The interview will cover topics including BioSante's market potential, growth initiatives, competitive edge, recent news, and milestones for which investors should watch.

To hear the interview in its entirety, visit http://www.wallst.net, and click on "Interviews." The interview can be accessed either by locating the company's ticker symbol under the appropriate exchange at the top of the "Interviews" section or by entering the company's ticker symbol in the Search Archive window on the right-hand column of the "Interviews" section once it is posted.

About BioSante Pharmaceuticals, Inc.

BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. BioSante's lead products include Elestrin(TM) (estradiol gel) developed through FDA approval by BioSante indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and LibiGel(R) (transdermal testosterone gel) in Phase III clinical development by BioSante for the treatment of female sexual dysfunction (FSD). Also in development is Bio-T-Gel(TM), a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, including hepatitis B, avian flu and biodefense vaccines for toxins such as anthrax, as well as a system for delivering drugs via alternative routes of administration and for aesthetic medicine. Additional information is available online at http://www.biosantepharma.com.

About WallSt.net:

http://www.wallst.net is owned and operated by WallStreet Direct, Inc., a wholly owned subsidiary of Financial Media Group, Inc. The Website is a leading provider of timely business news, executive interviews, multimedia content, and research tools. Financial Media Group, Inc. also owns http://www.mywallst.net, a financial social network for investors, Financial Filings Corp., a provider of compliance solutions to publicly traded companies, and WallStRadio, a business and finance podcast Website. Financial Filings Corp. is expecting to receive two hundred eighty dollars from BioSante Pharmaceuticals, Inc. for the dissemination of this press release. For a complete list of our advertisers and advertising relationships, visit http://www.wallst.net/disclaimer/disclaimer.asp.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050927/LATU121LOGO)

Contact: WallSt.net

800-4-WALL-ST


'/>"/>
SOURCE Financial Filings Corp.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... 19, 2016 - I dati ... durante il 52 ° Congresso ... - Le conclusioni dello studio indicano un ... trattati, di cui il 90% presenta una d urata ... più. Il settantadue per cento dei pazienti ha riscontrato un ...
(Date:5/18/2016)... The Biotech industry continues to face a wave ... no opportunities ahead. Today, ActiveWallSt.com has on its list these ... Seattle Genetics Inc. (NASDAQ: SGEN ), Chiasma Inc. ... OPHT ). Sign up now to receive our free ... Threshold Pharmaceuticals Inc.,s shares gained 0.68%, closing Tuesday,s ...
(Date:5/18/2016)... IN (PRWEB) , ... May 18, 2016 , ... The ... and is now celebrating its dream of reaching a total of $1 million in ... scholarships awarded to 10 high school graduates from across the nation has helped bring ...
(Date:5/17/2016)... ... May 17, 2016 , ... ... animal waste reduction applications, announced today it will be showcasing ManureMagicâ„¢ at booth ... ManureMagicâ„¢ was featured in the Wall Street Journal last year and more recently ...
Breaking Biology Technology:
(Date:3/9/2016)... March 9, 2016 This BCC Research report ... of the RNA Sequencing (RNA Seq) market for the ... instruments, tools and reagents, data analysis, and services. ... of the RNA-Sequencing market such as RNA-Sequencing tools and ... main factors affecting each segment and forecast their market ...
(Date:3/9/2016)... , March 9, 2016  Crossmatch ® ... and enrollment solutions, today announced the addition of ... Altus multi-factor authentication platform. New contextual ... managers to step-up security where it,s needed most ... Washington, DC . --> ...
(Date:3/3/2016)... 2016  FlexTech, a SEMI Strategic Association Partner, awarded ... & Development, Leadership in Education, and, in a category ... th year of the FLEXI Awards and the ... from past years . Judging was done on ... of criteria, by a panel of non-affiliated, independent, industry ...
Breaking Biology News(10 mins):